Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.

A novel synthetic crystalline aluminogermanosilicate molecular sieve material, designated SSZ-116, is provided. SSZ-116 can be synthesized using 3-[(3,5-di-tert-butylphenyl)methyl]-1,2-dimethyl-1H-imidazolium cations as a structure directing agent. SSZ-116 may be used in organic compound conversion reactions and/or sorptive processes. This disclosure also relates to the structure directing agents used in the methods for making the SSZ-116 material as well as the synthesis method used to prepare such structure directing agents.

The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and/or nematode astacins; more particularly human or mammalian meprin α, meprin β, BMP-1, ovastacin and/or DPY-31 from nematodes; pharmaceutical compositions comprising such compounds; methods for treatment or prophylaxis of diseases or conditions, especially such that are related to said metalloproteinases; and compounds and pharmaceutical compositions for use in such methods.

The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and/or nematode astacins; more particularly human or mammalian meprin α, meprin β, BMP-1, ovastacin and/or DPY-31 from nematodes; pharmaceutical compositions comprising such compounds; methods for treatment or prophylaxis of diseases or conditions, especially such that are related to said metalloproteinases; and compounds and pharmaceutical compositions for use in such methods.

Provided are: an ionic liquid including the fluorine-containing phosphate ester anions represented by formula (1); and a lubricating oil composition including said ionic liquid.

##STR00001##

(In the formula, Rf represents a C1-14 perfluoroalkyl group. R.sup.1 represents a C1-8 alkyl group.)

An electrolyte solution for a lithium ion secondary battery, containing a compound (1) represented by the following formula (1): ##STR00001##
wherein R.sup.1 and R.sup.2 are each independently a C1-C4 alkyl group optionally containing an ether bond, and wherein chloride ion is present at a concentration of 1.0×10.sup.−6 to 1.0×10.sup.3 ppm. Also disclosed is an electrolyte solution for a lithium ion secondary battery, containing an imidazolium cation (1-1) represented by the following formula (1-1), a bis(oxalato)borate anion, and a hexafluorophosphate anion, the formula (1-1) being: ##STR00002##
wherein R.sup.1 and R.sup.2 are each independently a C1-C4 alkyl group optionally containing an ether bond, and wherein chloride ion is present at a concentration of 1.0×10.sup.−6 to 1.0×10.sup.3 ppm.

An electrolyte solution for a lithium ion secondary battery, containing a compound (1) represented by the following formula (1): ##STR00001##
wherein R.sup.1 and R.sup.2 are each independently a C1-C4 alkyl group optionally containing an ether bond, and wherein chloride ion is present at a concentration of 1.0×10.sup.−6 to 1.0×10.sup.3 ppm. Also disclosed is an electrolyte solution for a lithium ion secondary battery, containing an imidazolium cation (1-1) represented by the following formula (1-1), a bis(oxalato)borate anion, and a hexafluorophosphate anion, the formula (1-1) being: ##STR00002##
wherein R.sup.1 and R.sup.2 are each independently a C1-C4 alkyl group optionally containing an ether bond, and wherein chloride ion is present at a concentration of 1.0×10.sup.−6 to 1.0×10.sup.3 ppm.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.

Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.

Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.